MBP Peptide Composition for Targeted Uveitis Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for uveitis, such as glucocorticoid steroids and immunosuppressive agents, are inadequate, necessitating the development of alternative therapies to effectively manage this inflammatory eye condition.
Innovation Solution
A composition comprising specific peptides derived from Myelin Basic Protein (MBP), including MBP 30-44, MBP 83-99, MBP 131-145, and MBP 140-154, which bind to MHC class II molecules, providing broad coverage of different Major Histocompatibility Complex haplotypes and reducing uveitis symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucocorticoid steroids and broad immunosuppressive agents are used to treat uveitis, then inflammation is suppressed, but side effects and lack of targeted efficacy increase
Solution Approach 1:
The invention segments the treatment approach by using multiple specific MBP-derived peptides (MBP 30-44, MBP 83-99, MBP 131-145, MBP 140-154) instead of a single broad immunosuppressive agent. Each peptide targets specific MHC class II molecules and haplotypes, dividing the treatment into targeted components that collectively address the autoimmune response without the broad side effects of traditional immunosuppressants
Solution Approach 2:
The invention applies local quality by designing peptides with specific binding affinities to particular MHC class II molecules and haplotypes. Each peptide has tailored properties for binding to specific immune targets (e.g., HLA-DR, HLA-DQ molecules), allowing precise modulation of the immune response in the uvea while preserving overall immune function and avoiding systemic side effects
2Adaptability or versatility
If a single peptide therapy is used, then treatment simplicity is maintained, but coverage of different MHC haplotypes is insufficient
Solution Approach 1:
The invention merges four distinct MBP-derived peptides into a single composition that collectively binds to multiple MHC class II molecules and covers diverse HLA haplotypes. This combination approach (MBP 30-44, MBP 83-99, MBP 131-145, MBP 140-154) provides comprehensive immune coverage that a single peptide cannot achieve alone, while the peptides can be administered together in one formulation
Solution Approach 2:
The peptide composition achieves universality by being effective across different MHC haplotypes and HLA types. The combination of peptides is designed to bind to various MHC class II molecules (HLA-DR, HLA-DQ, and other HLA types), making the treatment broadly applicable to different patient populations with diverse genetic backgrounds
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MBP peptides significantly reduce clinical signs of uveitis by inducing tolerance to self-antigens, suppressing immune responses, and preventing or treating uveitis in subjects, offering a more targeted and effective alternative to existing therapies.
Implementation Method 1
the peptides binds several MHC class II molecules including HLA-DR and -DQ molecules
Data Source
AI summary
The present invention relates to a composition comprising a peptide derived from myelin basic protein (MBP) peptide for use in treating or preventing uveitis in a subject